地塞米松剂量强度不影响新诊断多发性骨髓瘤的结局:一项SWOG二次分析
该研究是对SWOG 0777和SWOG 1211两项试验的汇总二次分析,纳入541例新诊断多发性骨髓瘤患者,评估地塞米松剂量降低对无进展生存期和总生存期的影响。结果显示,全剂量地塞米松组与降低剂量组在无进展生存期和总生存期上无差异,降低剂量组占69%。作者认为地塞米松减量在新诊断多发性骨髓瘤诱导中常见,值得进一步前瞻性研究。
要点
- 在541例可评估患者中,373例(69%)属于降低剂量地塞米松组。
- 全剂量地塞米松组与降低剂量组在无进展生存期和总生存期上无差异。
- 多变量模型中,治疗臂、年龄≥70岁和血小板减少是无进展生存期和总生存期的预测因素。
核心结论
- 本研究提示地塞米松剂量降低在多发性骨髓瘤中常见,即使在临床试验中也是如此。
- 鉴于现代治疗方案时代地塞米松的诸多毒性和不明确获益,新诊断多发性骨髓瘤诱导期间地塞米松减量值得进一步前瞻性研究。
研究设计与样本
- 对SWOG 0777和SWOG 1211两项新诊断多发性骨髓瘤研究进行汇总二次分析。
- 两项研究均使用来那度胺和地塞米松(Rd)方案,联合或不联合硼替佐米,联合或不联合埃罗妥珠单抗。
- 所有组别计划地塞米松强度为每周40至60 mg。
- 患者分为全剂量地塞米松组(诱导期间维持全剂量)和降低剂量地塞米松组(减量或停药;两项研究方案均仅允许因3级及以上毒性而减量)。
- 共评估541例患者,其中降低剂量地塞米松组373例(69%)。
主要发现
- 全剂量地塞米松组与降低剂量地塞米松组在无进展生存期和总生存期上无差异。
- 两组在年龄、分期和体能状态方面均衡。
- 多变量模型中,无进展生存期和总生存期的预测因素为治疗臂、年龄≥70岁和血小板减少。
- 全剂量地塞米松未显著改善无进展生存期或总生存期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dexamethasone is a key component of induction for newly diagnosed multiple myeloma (NDMM), despite common toxicities, including hyperglycemia and insomnia. In the randomized ECOG E4A03 trial, dexamethasone 40 mg once weekly was associated with lower mortality than higher doses. However, the performance of dexamethasone dose reductions below this threshold with regard to progression-free survival (PFS) and overall survival (OS) in NDMM has not been fully characterized. We conducted a secondary pooled analysis of the SWOG 0777 and SWOG 1211 studies of NDMM, which used lenalidomide and dexamethasone (Rd) alone, with or without bortezomib, and with or without elotuzumab. The planned dexamethasone intensity was 40 to 60 mg weekly in all arms. Patients were categorized into FD-DEX (full-dose dexamethasone maintained throughout induction) or LD-DEX (lowered-dose dexamethasone or discontinuation; only permitted for grade 3+ toxicities per both study protocols). Of the 541 evaluated patients, the LD-DEX group comprised 373 patients (69%). There were no differences in PFS or OS between the FD-DEX and LD-DEX groups, which were balanced in terms of age, stage, and performance status. Predictors of PFS and OS in the multivariate models were treatment arm, age ≥70 years, and thrombocytopenia. FD-DEX did not significantly improve either outcome. Our study suggests that dexamethasone dose reductions are common in multiple myeloma, even within clinical trials. Given the many toxicities and unclear benefits of dexamethasone in the era of modern treatment regimens, dexamethasone dose reduction during NDMM induction warrants further prospective studies. These trials were registered at www.clinicaltrials.gov as #NCT00644228 and NCT01668719.
引用
- Banerjee R, Sexton R, Cowan AJ, et al. Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. Blood. 2025. PMID: 39321347. doi:10.1182/blood.2024025939
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。